$SSKN
STRATA Skin Sciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000114036124046521 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $8.797M
YoY Change -0.62%
Cost Of Revenue $3.490M
YoY Change -10.47%
Gross Profit $5.307M
YoY Change 7.13%
Gross Profit Margin 60.33%
Selling, General & Admin $6.717M
YoY Change 26.24%
% of Gross Profit 126.57%
Research & Development $243.0K
YoY Change -2.02%
% of Gross Profit 4.58%
Depreciation & Amortization $1.239M
YoY Change -14.49%
% of Gross Profit 23.35%
Operating Expenses $6.960M
YoY Change 24.98%
Operating Profit -$1.653M
YoY Change 168.78%
Interest Expense -$469.0K
YoY Change -188.83%
% of Operating Profit
Other Income/Expense, Net -$469.0K
YoY Change 7.08%
Pretax Income -$2.122M
YoY Change 101.52%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.122M
YoY Change 101.52%
Net Earnings / Revenue -24.12%
Basic Earnings Per Share -$0.53
Diluted Earnings Per Share -$0.53
COMMON SHARES
Basic Shares Outstanding 4.171M 4.171M
Diluted Shares Outstanding 4.039M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.062M
YoY Change -0.97%
Cash & Equivalents $7.062M
Short-Term Investments
Other Short-Term Assets $1.631M
YoY Change -1.98%
Inventory $2.744M
Prepaid Expenses
Receivables $4.443M
Other Receivables $0.00
Total Short-Term Assets $15.88M
YoY Change -19.48%
LONG-TERM ASSETS
Property, Plant & Equipment $10.39M
YoY Change 25.81%
Goodwill $6.519M
YoY Change -25.95%
Intangibles $5.840M
YoY Change -39.31%
Long-Term Investments
YoY Change
Other Assets $231.0K
YoY Change 225.35%
Total Long-Term Assets $24.33M
YoY Change -11.45%
TOTAL ASSETS
Total Short-Term Assets $15.88M
Total Long-Term Assets $24.33M
Total Assets $40.21M
YoY Change -14.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.749M
YoY Change -44.6%
Accrued Expenses $8.524M
YoY Change 44.45%
Deferred Revenue $2.421M
YoY Change 1.51%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.05M
YoY Change 16.81%
LONG-TERM LIABILITIES
Long-Term Debt $15.15M
YoY Change 0.91%
Other Long-Term Liabilities $1.477M
YoY Change -59.57%
Total Long-Term Liabilities $15.15M
YoY Change 0.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.05M
Total Long-Term Liabilities $15.15M
Total Liabilities $30.86M
YoY Change -0.45%
SHAREHOLDERS EQUITY
Retained Earnings -$243.6M
YoY Change 4.01%
Common Stock $4.000K
YoY Change -88.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.343M
YoY Change
Total Liabilities & Shareholders Equity $40.21M
YoY Change -14.81%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.122M
YoY Change 101.52%
Depreciation, Depletion And Amortization $1.239M
YoY Change -14.49%
Cash From Operating Activities -$302.0K
YoY Change -69.65%
INVESTING ACTIVITIES
Capital Expenditures $62.00K
YoY Change -92.49%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$62.00K
YoY Change -92.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.943M
YoY Change -1882.57%
NET CHANGE
Cash From Operating Activities -302.0K
Cash From Investing Activities -62.00K
Cash From Financing Activities 1.943M
Net Change In Cash 1.579M
YoY Change -181.81%
FREE CASH FLOW
Cash From Operating Activities -$302.0K
Capital Expenditures $62.00K
Free Cash Flow -$364.0K
YoY Change -80.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 us-gaap Other Liabilities And Deferred Revenue Noncurrent
OtherLiabilitiesAndDeferredRevenueNoncurrent
552000
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
1135000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1334000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1334000
CY2024Q3 us-gaap Inventory Net
InventoryNet
2744000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2673000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
297000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11778000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1348000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
626000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5840000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7319000
CY2024Q3 us-gaap Goodwill
Goodwill
6519000
CY2023Q4 us-gaap Goodwill
Goodwill
6519000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2024Q3 us-gaap Assets
Assets
40205000
CY2023Q4 us-gaap Assets
Assets
42016000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1749000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3343000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8524000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6306000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2421000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2120000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
322000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
352000
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
1030000
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
53000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14046000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12174000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15153000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15044000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.1
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12688000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40205000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42016000
CY2024Q3 us-gaap Other Liabilities And Deferred Revenue Noncurrent
OtherLiabilitiesAndDeferredRevenueNoncurrent
379000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8797000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8852000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
3490000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
3898000
CY2024Q3 us-gaap Gross Profit
GrossProfit
5307000
CY2023Q3 us-gaap Gross Profit
GrossProfit
4954000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
243000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
248000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3048000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3038000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3669000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2283000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
6960000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
5569000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1653000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-615000
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
537000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
528000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
68000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2122000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1053000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4038988
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3491113
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3491113
us-gaap Net Income Loss
NetIncomeLoss
-7036000
us-gaap Share Based Compensation
ShareBasedCompensation
301000
us-gaap Share Based Compensation
ShareBasedCompensation
1014000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-38000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-55000
us-gaap Inventory Write Down
InventoryWriteDown
141000
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-909000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-37000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
126000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-14000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
209000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-388000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1638000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-268000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2176000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-611000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
170000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-165000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-242000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-279000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-515000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1890000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
42000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
97000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1670000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8118000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6795000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8396000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8465000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7062000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7131000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1334000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1334000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8396000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8465000
us-gaap Interest Paid Net
InterestPaidNet
1490000
us-gaap Interest Paid Net
InterestPaidNet
917000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
977000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
sskn Transfer Of Property And Equipment To Inventories
TransferOfPropertyAndEquipmentToInventories
226000
sskn Transfer Of Property And Equipment To Inventories
TransferOfPropertyAndEquipmentToInventories
234000
sskn Accrued Payment Of Contingent Consideration
AccruedPaymentOfContingentConsideration
44000
sskn Accrued Payment Of Contingent Consideration
AccruedPaymentOfContingentConsideration
0
sskn Modification Of Common Stock Warrants
ModificationOfCommonStockWarrants
0
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Use of Estimates</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and judgments include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of contingent consideration, state sales and use tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.</span> </div>
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001051514
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity File Number
EntityFileNumber
0-51481
dei Entity Registrant Name
EntityRegistrantName
STRATA SKIN SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3986004
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Walnut Grove Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 140
dei Entity Address City Or Town
EntityAddressCityOrTown
Horsham
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19044
dei City Area Code
CityAreaCode
215
dei Local Phone Number
LocalPhoneNumber
619-3200
dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
dei Trading Symbol
TradingSymbol
SSKN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4171161
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7062000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6784000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
159000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
222000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4443000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4440000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
312000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
15880000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
15543000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10387000
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
186000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
186000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1002000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
237000
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
96000
CY2024Q3 us-gaap Liabilities
Liabilities
30862000
CY2023Q4 us-gaap Liabilities
Liabilities
29328000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.1
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4171161
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4171161
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3506025
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3506025
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
252986000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
250742000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243647000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238058000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
9343000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23986000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24669000
us-gaap Cost Of Revenue
CostOfRevenue
10662000
us-gaap Cost Of Revenue
CostOfRevenue
11009000
us-gaap Gross Profit
GrossProfit
13324000
us-gaap Gross Profit
GrossProfit
13660000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
683000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
937000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9080000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10196000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8589000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7690000
us-gaap Costs And Expenses
CostsAndExpenses
18352000
us-gaap Costs And Expenses
CostsAndExpenses
18823000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5028000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5163000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-909000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1592000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1112000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
90000
us-gaap Investment Income Interest
InvestmentIncomeInterest
167000
us-gaap Investment Income Interest
InvestmentIncomeInterest
148000
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
864000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-469000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-438000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-561000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1873000
us-gaap Net Income Loss
NetIncomeLoss
-5589000
us-gaap Net Income Loss
NetIncomeLoss
-7036000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4038988
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3684976
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3684976
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3488465
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3488465
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12688000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
112000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3368000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9432000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
163000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-99000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9496000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1943000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2122000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
9343000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21831000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
325000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2835000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
19321000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
352000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
384000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3148000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16909000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
337000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1053000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
16193000
us-gaap Net Income Loss
NetIncomeLoss
-5589000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3738000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4274000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
255000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
257000
sskn Amortization Of Debt Issuance Costs And Debt Discount Premium
AmortizationOfDebtIssuanceCostsAndDebtDiscountPremium
109000
sskn Amortization Of Debt Issuance Costs And Debt Discount Premium
AmortizationOfDebtIssuanceCostsAndDebtDiscountPremium
112000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-40000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-205000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1132000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3301000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1132000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3301000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
18000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1943000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1925000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6861000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
278000
sskn Modification Of Common Stock Warrants
ModificationOfCommonStockWarrants
384000
sskn Accrued Exit Fee Recorded As Debt Discount
AccruedExitFeeRecordedAsDebtDiscount
150000
sskn Accrued Exit Fee Recorded As Debt Discount
AccruedExitFeeRecordedAsDebtDiscount
450000
sskn Change In Intangible Assets And Fair Value Of Contingent Consideration
ChangeInIntangibleAssetsAndFairValueOfContingentConsideration
0
sskn Change In Intangible Assets And Fair Value Of Contingent Consideration
ChangeInIntangibleAssetsAndFairValueOfContingentConsideration
5616000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;">Reclassifications</div> <div style="display:none;"><br/></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;">Certain prior year amounts have been reclassified to conform to the current year presentation, including the impact on the condensed consolidated statement of cash flows of the reclassification of lasers-in-process from inventories to property and equipment, net.</div>
CY2024Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
293000
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
269000
CY2023Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
303000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
207000
CY2024Q3 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
72000
CY2023Q3 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
72000
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
187000
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
192000
CY2024Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
119000
CY2023Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
47000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
244000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
105000
CY2024Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
246000
CY2023Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
294000
CY2024Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
246000
CY2023Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
294000
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
165000
CY2023Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
180000
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
165000
CY2023Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
180000
CY2024Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
81000
CY2023Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
114000
CY2024Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
81000
CY2023Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
114000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
583991
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
612138
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
CY2024Q3 us-gaap Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
P1Y
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
516000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
218000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q3 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
218000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
298000
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
71000
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
88000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
225000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
324000
CY2024Q3 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2400000
CY2023Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2192000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
344000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
481000
CY2024Q3 us-gaap Inventory Net
InventoryNet
2744000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2673000
us-gaap Inventory Write Down
InventoryWriteDown
141000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36139000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36062000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25752000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24284000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10387000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11778000
CY2024Q3 us-gaap Depreciation
Depreciation
745000
CY2023Q3 us-gaap Depreciation
Depreciation
729000
us-gaap Depreciation
Depreciation
2259000
us-gaap Depreciation
Depreciation
2119000
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24222000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18382000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5840000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24222000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16903000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7319000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
494000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
720000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1479000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2155000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
492000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1266000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
561000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
561000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
561000
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
165000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
180000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1788000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1679000
CY2024Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
6155000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
4316000
CY2024Q3 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
416000
CY2023Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
131000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8524000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6306000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3750000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7500000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
3750000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
15000000
CY2024Q3 sskn Debt Instrument Exit Fee
DebtInstrumentExitFee
600000
CY2024Q3 sskn Long Term Debt After Exit Fee
LongTermDebtAfterExitFee
15600000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
447000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15153000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
337000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
301000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1014000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.777
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.038
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8797000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23986000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
3490000
us-gaap Cost Of Revenue
CostOfRevenue
10662000
CY2024Q3 us-gaap Gross Profit
GrossProfit
5307000
us-gaap Gross Profit
GrossProfit
13324000
CY2024Q3 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.603
sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.555
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
243000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
683000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3048000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9080000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3669000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8589000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
6960000
us-gaap Costs And Expenses
CostsAndExpenses
18352000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1653000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5028000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
537000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1592000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
68000
us-gaap Investment Income Interest
InvestmentIncomeInterest
167000
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
864000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2122000
us-gaap Net Income Loss
NetIncomeLoss
-5589000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8852000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24669000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
3898000
us-gaap Cost Of Revenue
CostOfRevenue
11009000
CY2023Q3 us-gaap Gross Profit
GrossProfit
4954000
us-gaap Gross Profit
GrossProfit
13660000
CY2023Q3 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.56
sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.554
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
248000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
937000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3038000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10196000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2283000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7690000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
5569000
us-gaap Costs And Expenses
CostsAndExpenses
18823000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-615000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5163000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-909000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
528000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1112000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
90000
us-gaap Investment Income Interest
InvestmentIncomeInterest
148000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1053000
us-gaap Net Income Loss
NetIncomeLoss
-7036000
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1239000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1449000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3738000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4274000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8797000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23986000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8852000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24669000
CY2024Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
sskn Change In Operating Lease Right Of Use Assets And Liability Due To Amended Lease
ChangeInOperatingLeaseRightOfUseAssetsAndLiabilityDueToAmendedLease
977000
sskn Change In Operating Lease Right Of Use Assets And Liability Due To Amended Lease
ChangeInOperatingLeaseRightOfUseAssetsAndLiabilityDueToAmendedLease
0
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
122000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
106000
us-gaap Operating Lease Cost
OperatingLeaseCost
350000
us-gaap Operating Lease Cost
OperatingLeaseCost
335000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
112000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
110000
us-gaap Operating Lease Payments
OperatingLeasePayments
336000
us-gaap Operating Lease Payments
OperatingLeasePayments
315000
sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.1209
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
116000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
463000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
334000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
290000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
301000
CY2024Q3 sskn Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
231000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1735000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
411000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1324000
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001140361-24-046521-index-headers.html Edgar Link pending
0001140361-24-046521-index.html Edgar Link pending
0001140361-24-046521.txt Edgar Link pending
0001140361-24-046521-xbrl.zip Edgar Link pending
ef20034537_10q.htm Edgar Link pending
ef20034537_ex31-1.htm Edgar Link pending
ef20034537_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ef20034537_10q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sskn-20240930.xsd Edgar Link pending
sskn-20240930_def.xml Edgar Link unprocessable
sskn-20240930_lab.xml Edgar Link unprocessable
sskn-20240930_cal.xml Edgar Link unprocessable
sskn-20240930_pre.xml Edgar Link unprocessable